A Phase 2 interventional study of VLA15 and Placebo in Lyme Borreliosis, sponsored by Pfizer. Completed at 9 sites in 3 countries. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-01-10.
Sponsored by Pfizer · Phase 2, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 54 studies in Lyme Disease with a site in United States — 15 open to participants now, 17 under way, 2 of them phase 3. Lyme Disease · United States.
Among the 54 studies in Lyme Disease with a site in United States, this one is the 8th largest by enrollment of the 33 interventional ones that give a count, is one of 3 that started in 2018, is one of 6 in phase 2, and was the 23rd registered.
98 studies on the registry are indexed under Lyme Disease; 27 are open to participants now.
Browse Lyme Disease studies →15 of the 54 studies in Lyme Disease with a site in United States are open now. Recruiting first, the newest first:
Pfizer · Sites in United States, Canada
Ages 7+ · Healthy volunteers
Columbia University · Sites in United States
Ages 18–70
Icahn School of Medicine at Mount Sinai · Sites in United States
Ages 18+
Children's National Research Institute · Sites in United States
Ages 18+ · Women only
Children's National Research Institute · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 18 Lyme Disease studies recruiting now, 11 (61%) set no upper age limit and 3 (17%) stop at 75 or younger; 7 take children under 18; 5 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
54 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 10 · Phase 3 10
First in 1996; this study’s year is marked. 3 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 572 is above the median of 120 across 52 interventional studies indexed under Lyme Disease.
Median enrollment 72 across the 33 interventional studies, 410 across the 21 observational. Of the 30 that completed or were terminated, 12 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
21 of 54 have an industry lead sponsor. The 10 most frequent:
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
Pfizer has 8 studies filed under Lyme Disease — fewer than ten, so there is no comparison to draw.
7 of the studies in Lyme Disease with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07500506Phase 3PfizerA Study to Learn About the Safety, Tolerability, and Immunogenicity of a Fifth Dose of 6-Valent OspA-Based Lyme Disease Vaccine | 2026-12-04 |
| NCT05776251Columbia UniversitytaVNS for Persistent Symptoms From Lyme Disease | 2026-11 |
| NCT06026969Children's National Research InstitutePregnancy and Early Neurodevelopmental Outcomes Following In Utero Lyme Disease Exposure | 2026-12 |
| NCT06511050Icahn School of Medicine at Mount SinaiLumbrokinase for Adults With Long Covid, Post-treatment Lyme Disease Syndrome, and Myalgic Encephalomyelitis/Chronic Fatigue Syndrome | 2026-12 |
| NCT06397794Children's National Research InstituteNavigating Pregnancy and Parenthood With Lyme Disease | 2026-12-01 |
Add all 7 to your calendar (.ics) → With an account.
Among the 54 studies in Lyme Disease with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a randomized, observer-blind, placebo controlled, multicenter Phase 2 study conducted in two study phases: a run-in phase and a main study phase. The study was investigated 3 doses of a multivalent OspA (Outer Surface Protein A) based Lyme vaccine (VLA15) in healthy adults aged 18 to 65 years of age. Study participants received 3 immunizations of the vaccine at a monthly interval. The study assessed the immune response as well as the safety profile of the vaccine.
This is a randomized, observer-blind, placebo controlled, multicenter Phase 2 study.
In the Run-in phase, a total of 120 subjects aged 18 to 40 years were randomized 1:1:1:1 to receive one of three VLA15 doses (VLA15 low dose (90 µg), VLA15 medium dose (135 µg), VLA15 high dose (180 µg)) or Placebo as intramuscular vaccinations on Days 1, 29 and 57.
Dosing was adjusted by injection volume.
In the Main Study phase, a total of 452 subjects aged 18 to 65 years were randomized 2:2:1 to receive VLA15 135 µg or VLA15 180 µg, the two dose groups were selected from the Run-in-Phase or placebo, as intramuscular vaccinations on Days 1, 29 and 57. Subjects were enrolled in two age groups (18-49 years and 50-65 years) in a ratio of approx. 2:1.
In both study phases, target was to enroll approx. 10 % or more of subjects that were baseline seropositive for Borrelia burgdorferi sensu latu (Bb s.l.).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Run-in phase:
Main Study phase:
Subject is aged18 to 65 years at the day of screening (Visit 0);
Run-in phase and Main Study phase:
If subject is of :
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
VLA15 low dose with Alum.
Biological: VLA15
VLA15 medium dose with Alum.
Biological: VLA15
VLA15 high dose with Alum.
Biological: VLA15
Biological: Placebo
a multivalent recombinant Outer surface protein A (OspA) based vaccine candidate
Placebo: PBS (Phosphate Buffered Saline)
GMTs (Geometric Mean Titers) for IgG (Immunoglobulin G) Against Each OspA (Outer Surface Protein A) Serotype ST1 to ST6
GMTs (Geometric Mean Titers) for IgG (Immunoglobulin G) against each OspA (Outer Surface Protein A) serotype ST1 to ST6, determined by ELISA at Day 85. GMTs are calculated based on the number of subjects with non-missing results.
Time frame: at Day 85 / Month 3
GMTs (Geometric Mean Titers) for IgG (Immunoglobulin G) Against Each OspA (Outer Surface Protein A) Serotype (ST1 to ST6)
GMTs (Geometric Mean Titers) for IgG (Immunoglobulin G) against each OspA (Outer Surface Protein A) (Outer Surface Protein A) serotype (ST1 to ST6), determined by ELISA. GMTs are calculated based on the number of subjects with non-missing results.
Time frame: up to Day 365 / Month 12
SCRs (Seroconversion Rate) for Each OspA (Outer Surface Protein A) Serotype Specific IgG (Immunoglobulin G) (ST1 to ST6),
Seroconversion for ELISA is defined as: * for subjects that are seronegative at Visit 1 (baseline): a change from seronegative at Visit 1 to seropositive (i.e. antibody titer of ≥40 U/mL) at a certain time point. * for subjects that are seropositive at Visit 1 (baseline): a ≥ 4-fold rise in IgG antibody titer from Visit 1. Percentages are based on the number of subjects with non-missing observations.
Time frame: up to Day 365 / Month 12
GMFR (Geometric Mean of the Fold Rise as Compared to Baseline) for IgG (Immunoglobulin G) Against Each OspA (Outer Surface Protein A) Serotype (ST1 to ST6)
GMFR (Geometric Mean of the Fold Rise as compared to baseline) for IgG (Immunoglobulin G) against each OspA (Outer Surface Protein A) serotype (ST1 to ST6), determined by ELISA. Calculations are based on number of subjects with non-missing results.
Time frame: up to Day 365 / Month 12
GMTs (Geometric Mean Titers) for IgG (Immunoglobulin G) Against Each OspA (Outer Surface Protein A) Serotype (ST1 to ST6) - Group 18 - 49 Years
GMTs (Geometric Mean Titers) for IgG (Immunoglobulin G) against each OspA (Outer Surface Protein A) serotype (ST1 to ST6), determined by ELISA, stratified by age group - Group 18 - 49 years. GMTs are calculated based on the number of subjects with non-missing results.
Time frame: up to Day 365 / Month 12
GMTs (Geometric Mean Titers) for IgG (Immunoglobulin G) Against Each OspA (Outer Surface Protein A) Serotype (ST1 to ST6) - Group 50 - 65 Years
GMTs (Geometric Mean Titers) for IgG (Immunoglobulin G) Against Each OspA (Outer Surface Protein A) Serotype (ST1 to ST6), determined by ELISA, stratified by age group - Group 50 - 65 years. GMTs are calculated based on the number of subjects with non-missing results.
Time frame: up to Day 365 / Month 12
SCRs (Seroconversion Rate) for IgG (Immunoglobulin G) Against Each OspA (Outer Surface Protein A) Serotype (ST1 to ST6) - Group 18 - 49 Years
SCRs (Seroconversion Rate) for Seroconversion for ELISA is defined as: * for subjects that are seronegative at Visit 1 (baseline): a change from seronegative at Visit 1 to seropositive (i.e. antibody titer of ≥40 U/mL) at a vertain time point. * for subjects that are seropositive at Visit 1 (baseline): a ≥ 4-fold rise in IgG antibody titer from Visit 1. Percentages are based on the number of subjects with non-missing observations.
Time frame: up to Day 365 / Month 12
SCRs (Seroconversion Rate) for IgG (Immunoglobulin G) Against Each OspA (Outer Surface Protein A) Serotype (ST1 to ST6) - Group 50 - 65 Years
Seroconversion for ELISA is defined as: * for subjects that are seronegative at Visit 1 (baseline): a change from seronegative at Visit 1 to seropositive (i.e. antibody titer of ≥40 U/mL) at a vertain time point. * for subjects that are seropositive at Visit 1 (baseline): a ≥ 4-fold rise in IgG antibody titer from Visit 1. Percentages are based on the number of subjects with non-missing observations.
Time frame: up to Day 365 / Month 12
GMFRs (Geometric Mean of the Fold Rise as Compared to Baseline) for IgG (Immunoglobulin G) Against Each OspA (Outer Surface Protein A) Serotype (ST1 to ST6) - Group 18 - 49 Years
GMFRs (Geometric Mean of the Fold Rise as Compared to Baseline) for IgG (Immunoglobulin G) Against Each OspA (Outer Surface Protein A) Serotype (ST1 to ST6), stratified by age group - Group 18 - 49 years. Calculations are based on number of subjects with non-missing results.
Time frame: up to Day 365 / Month 12
GMFRs (Geometric Mean of the Fold Rise as Compared to Baseline) for IgG (Immunoglobulin G) Against Each OspA (Outer Surface Protein A) Serotype (ST1 to ST6) - Group 50 - 65 Years
GMFRs (Geometric Mean of the Fold Rise as Compared to Baseline) for IgG (Immunoglobulin G) Against Each OspA (Outer Surface Protein A) Serotype (ST1 to ST6), stratified by age group - Group 50 - 65 years. Calculations are based on number of subjects with non-missing results.
Time frame: up to Day 365 / Month 12
Percentage of Participants With SAEs (Serious Adverse Events)
Frequency of SAEs (Serious Adverse Events) during the entire study; frequency is being assessed in terms of percentage of participants.
Time frame: up to Day 365 / Month 12
Percentage of Participants With Related SAEs (Serious Adverse Events)
Frequency of related SAEs (Serious Adverse Events) during the entire study; frequency is being assessed in terms of percentage of participants.
Time frame: up to Day 365 / Month 12
Percentage of Participants With AESIs (Adverse Events of Special Interest)
Frequency of AESIs (Adverse Events of Special Interest) during the entire study; frequency is being assessed in terms of percentage of participants. AESIs are cases of Lyme Diseases, Lyme associated Events and the onset of potentially autoimmune or neuro-inflammatory disorders.
Time frame: up to Day 365 / Month 12
Percentage of Participants With Related AESIs (Adverse Events of Special Interest)
Frequency of related AESIs (Adverse Events of Special Interest) during the entire study; frequency is being assessed in terms of percentage of participants. AESIs are cases of Lyme Diseases, Lyme associated Events and the onset of potentially autoimmune or neuro-inflammatory disorders.
Time frame: up to Day 365 / Month 12
Percentage of Participants With Unsolicited AEs (Adverse Events)
Frequency of unsolicited AEs (Adverse Events) during the entire study (incl. clinically relevant laboratory parameters); frequency is being assessed in terms of percentage of participants.
Time frame: up to Day 365 / Month 12
Percentage of Participants With Related Unsolicited AEs (Adverse Events)
Frequency of related unsolicited AEs (Adverse Events) during the entire study (incl. clinically relevant laboratory parameters); frequency is being assessed in terms of percentage of participants.
Time frame: up to Day 365 / Month 12
Percentage of Participants With Solicited Local and Solicited Systemic AEs (Adverse Events)
Frequency of solicited local and solicited systemic AEs (Adverse Events) within 7 days after each and after any vaccination; frequency is being assessed in terms of percentage of participants.
Time frame: Day 1 (day of first vaccination) through Day 7; Day 29 (day of second vaccination) through Day 35; Day 57 (day of third vaccination) through Day 63
Percentage of Participants With SAEs (Serious Adverse Events), AESIs (Adverse Events of Special Interest), Solicited and Unsolicited AEs (Adverse Events) - Group 18-49
Frequency of SAEs (Serious Adverse Events), AESIs (Adverse Events of Special Interest), solicited and unsolicited AEs (Adverse Events) during the entire study stratified by age group - Group 18-49; frequency is being assessed in terms of percentage of participants.
Time frame: up to Day 365 / Month 12
Percentage of Participants With SAEs (Serious Adverse Events), AESIs (Adverse Events of Special Interest), Solicited and Unsolicited AEs (Adverse Events) - Group 50-65 Years
Frequency of SAEs (Serious Adverse Events), AESIs (Adverse Events of Special Interest), Solicited and Unsolicited AEs (Adverse Events) during the entire study stratified by age group - Group 50-65 years; frequency is being assessed in terms of percentage of participants.
Time frame: up to Day 365 / Month 12
Number of Participants With AESIs (Adverse Events of Special Interest) up to Study End
Time frame: up to Day 365 / Month 12
| Milestone | VLA15 Low Dose | VLA15 Medium Dose | VLA15 High Dose | Placebo |
|---|---|---|---|---|
| Started | 29 | 214 | 205 | 124 |
| Completed | 25 | 196 | 197 | 115 |
| Not completed | 4 | 18 | 8 | 9 |
| Withdrew: Withdrawal by subject | 0 | 7 | 4 | 1 |
| Withdrew: Moved from study area | 0 | 2 | 1 | 1 |
| Withdrew: Lost to follow-up | 3 | 6 | 3 | 6 |
| Withdrew: Other | 1 | 3 | 0 | 1 |
GMTs (Geometric Mean Titers) for IgG (Immunoglobulin G) against each OspA (Outer Surface Protein A) serotype ST1 to ST6, determined by ELISA at Day 85. GMTs are calculated based on the number of subjects with non-missing results.
| U/mL | VLA15 Low Dose | VLA15 Medium Dose | VLA15 High Dose | Placebo |
|---|---|---|---|---|
| ST1 Day 85 | 74.3 (46.4 to 119.0) | 101.9 (87.1 to 119.4) | 115.8 (98.8 to 135.7) | 21.7 (20.0 to 23.6) |
| ST2 Day 85 | 180.9 (124.8 to 262.3) | 279.3 (247.1 to 315.8) | 303.7 (266.5 to 346.1) | 21.1 (20.0 to 22.3) |
| ST3 Day 85 | 267.4 (194.8 to 367.1) | 283.2 (248.2 to 323.1) | 308.6 (266.8 to 356.8) | 20.8 (19.8 to 21.8) |
| ST4 Day 85 | 117.0 (76.6 to 178.7) | 170.9 (150.5 to 194.2) | 190.7 (165.9 to 219.2) | 21.8 (20.4 to 23.4) |
| ST5 Day 85 | 118.3 (78.3 to 178.9) | 176.0 (154.2 to 201.0) | 199.6 (172.5 to 230.9) | 21.4 (20.2 to 22.6) |
| ST6 Day 85 | 115.6 (76.5 to 174.7) | 183.6 (161.7 to 208.4) | 208.7 (181.8 to 239.6) | 21.8 (20.3 to 23.4) |
GMTs (Geometric Mean Titers) for IgG (Immunoglobulin G) against each OspA (Outer Surface Protein A) (Outer Surface Protein A) serotype (ST1 to ST6), determined by ELISA. GMTs are calculated based on the number of subjects with non-missing results.
| U/mL | VLA15 Low Dose | VLA15 Medium Dose | VLA15 High Dose | Placebo |
|---|---|---|---|---|
| ST1 Day 1 | 20.8 (19.2 to 22.5) | 20.5 (19.8 to 21.3) | 20.2 (19.8 to 20.6) | 21.6 (19.9 to 23.5) |
| ST1 Day 29 | 21.1 (18.9 to 23.5) | 21.8 (20.0 to 23.8) | 21.2 (20.1 to 22.4) | 21.7 (20.0 to 23.7) |
| ST1 Day 57 | 32.7 (25.1 to 42.6) | 37.5 (32.4 to 43.3) | 41.2 (35.7 to 47.5) | 21.9 (20.1 to 23.8) |
| ST1 Day 180 | 26.2 (19.9 to 34.5) | 32.8 (28.8 to 37.3) | 33.9 (30.0 to 38.3) | 21.0 (19.8 to 22.3) |
| ST1 Day 236 | 22.2 (18.8 to 26.1) | 25.7 (22.8 to 28.8) | 26.2 (23.1 to 29.7) | 21.5 (19.6 to 23.6) |
| ST1 Day 365 | 20.9 (19.1 to 22.9) | 23.4 (21.4 to 25.6) | 23.0 (21.3 to 24.9) | 21.4 (19.9 to 22.9) |
| ST2 Day 1 | 21.3 (18.7 to 24.2) | 20.0 (20.0 to 20.0) | 20.1 (19.9 to 20.2) | 20.7 (19.7 to 21.8) |
| ST2 Day 29 | 21.1 (18.9 to 23.7) | 21.1 (20.0 to 22.2) | 21.4 (20.5 to 22.4) | 21.0 (19.9 to 22.1) |
| ST2 Day 57 | 69.0 (47.7 to 99.8) | 89.2 (75.9 to 104.9) | 107.8 (92.7 to 125.2) | 21.3 (20.0 to 22.6) |
| ST2 Day 180 | 41.2 (29.3 to 57.9) | 62.5 (54.5 to 71.7) | 67.1 (58.3 to 77.1) | 20.6 (19.7 to 21.5) |
| ST2 Day 236 | 26.6 (21.2 to 33.4) | 36.8 (32.1 to 42.2) | 35.7 (30.9 to 41.2) | 20.5 (19.5 to 21.5) |
| ST2 Day 365 | 21.8 (19.2 to 24.7) | 24.6 (22.8 to 26.6) | 24.8 (23.1 to 26.6) | 20.6 (19.7 to 21.5) |
| ST3 Day 1 | 21.9 (19.1 to 25.1) | 20.4 (20.0 to 20.8) | 20.1 (19.9 to 20.4) | 20.4 (19.6 to 21.2) |
| ST3 Day 29 | 23.7 (20.0 to 28.0) | 21.7 (20.2 to 23.2) | 21.2 (20.3 to 22.1) | 20.8 (19.8 to 21.9) |
| ST3 Day 57 | 110.2 (71.1 to 171.0) | 123.8 (104.4 to 146.9) | 145.8 (122.8 to 173.0) | 21.2 (20.0 to 22.6) |
| ST3 Day 180 | 53.1 (35.6 to 79.1) | 63.1 (55.2 to 72.2) | 68.7 (59.5 to 79.2) | 20.5 (19.8 to 21.3) |
| ST3 Day 236 | 35.3 (25.7 to 48.6) | 35.8 (31.2 to 41.1) | 39.0 (33.3 to 45.8) | 20.6 (19.7 to 21.7) |
| ST3 Day 365 | 25.2 (19.9 to 31.8) | 25.6 (23.5 to 27.9) | 27.0 (24.5 to 29.8) | 20.5 (19.8 to 21.3) |
| ST4 Day 1 | 21.4 (18.7 to 24.4) | 21.0 (20.3 to 21.7) | 20.2 (19.9 to 20.6) | 21.7 (20.3 to 23.2) |
| ST4 Day 29 | 22.1 (19.1 to 25.6) | 21.9 (20.4 to 23.6) | 21.4 (20.4 to 22.4) | 22.0 (20.4 to 23.6) |
| ST4 Day 57 | 45.9 (32.8 to 64.2) | 57.4 (49.5 to 66.6) | 64.7 (55.5 to 75.5) | 22.0 (20.4 to 23.8) |
| ST4 Day 180 | 32.8 (24.1 to 44.6) | 48.1 (42.5 to 54.5) | 49.3 (43.1 to 56.3) | 21.5 (20.2 to 22.9) |
| ST4 Day 236 | 25.5 (20.6 to 31.5) | 32.8 (29.0 to 37.2) | 31.9 (27.7 to 36.6) | 21.7 (20.0 to 23.5) |
| ST4 Day 365 | 21.8 (19.2 to 24.7) | 26.5 (24.2 to 28.9) | 25.5 (23.2 to 27.9) | 21.7 (20.3 to 23.2) |
| ST5 Day 1 | 20.6 (19.4 to 21.8) | 20.7 (20.1 to 21.3) | 20.2 (19.8 to 20.5) | 21.4 (20.2 to 22.7) |
| ST5 Day 29 | 20.7 (19.2 to 22.4) | 21.2 (20.0 to 22.5) | 21.0 (20.2 to 21.9) | 21.4 (20.1 to 22.7) |
| ST5 Day 57 | 42.7 (29.8 to 61.3) | 57.9 (44.9 to 67.2) | 72.2 (61.6 to 84.7) | 21.5 (20.2 to 22.9) |
| ST5 Day 180 | 26.7 (20.7 to 34.3) | 44.0 (38.8 to 49.8) | 50.0 (43.5 to 57.4) | 21.1 (20.0 to 22.3) |
| ST5 Day 236 | 23.0 (19.6 to 27.0) | 31.0 (27.5 to 35.0) | 32.4 (28.0 to 37.4) | 21.5 (20.0 to 23.1) |
| ST5 Day 365 | 21.7 (19.3 to 24.3) | 24.0 (22.3 to 25.8) | 24.9 (22.7 to 27.2) | 21.1 (20.0 to 22.2) |
| ST6 Day 1 | 21.1 (18.9 to 23.5) | 21.3 (20.4 to 22.2) | 20.8 (20.1 to 21.6) | 21.6 (20.2 to 23.2) |
| ST6 Day 29 | 21.1 (18.9 to 23.6) | 22.7 (21.2 to 24.3) | 22.0 (20.9 to 23.2) | 22.0 (20.4 to 23.7) |
| ST6 Day 57 | 42.3 (29.8 to 60.1) | 55.5 (48.1 to 64.1) | 65.3 (55.6 to 76.7) | 22.1 (20.4 to 23.9) |
| ST6 Day 180 | 30.1 (22.6 to 40.2) | 48.4 (42.8 to 54.8) | 51.4 (44.7 to 59.0) | 21.4 (20.1 to 22.8) |
| ST6 Day 236 | 25.6 (20.7 to 31.8) | 33.4 (29.5 to 37.8) | 33.2 (28.6 to 38.6) | 22.1 (20.2 to 24.3) |
| ST6 Day 365 | 22.1 (19.2 to 25.5) | 25.7 (23.8 to 27.9) | 26.0 (23.6 to 28.7) | 21.8 (20.3 to 23.3) |
Seroconversion for ELISA is defined as: * for subjects that are seronegative at Visit 1 (baseline): a change from seronegative at Visit 1 to seropositive (i.e. antibody titer of ≥40 U/mL) at a certain time point. * for subjects that are seropositive at Visit 1 (baseline): a ≥ 4-fold rise in IgG antibody titer from Visit 1. Percentages are based on the number of subjects with non-missing observations.
| percentage of subjects | VLA15 Low Dose | VLA15 Medium Dose | VLA15 High Dose | Placebo |
|---|---|---|---|---|
| ST1 Day 29 | 0.0 (0.0 to 11.7) | 3.7 (1.8 to 7.4) | 3.1 (1.4 to 6.6) | 0.8 (0.1 to 4.6) |
| ST1 Day 57 | 39.3 (23.6 to 57.6) | 37.2 (30.6 to 44.2) | 40.7 (34.1 to 47.8) | 1.7 (0.5 to 5.8) |
| ST1 Day 180 | 11.5 (4.0 to 29.0) | 32.8 (26.4 to 39.9) | 35.4 (29.0 to 42.5) | 0.9 (0.2 to 4.8) |
| ST1 Day 236 | 7.7 (2.1 to 24.1) | 17.2 (11.5 to 24.9) | 18.5 (12.5 to 26.4) | 2.6 (0.7 to 9.1) |
| ST1 Day 365 | 4.0 (0.7 to 19.5) | 10.9 (7.2 to 16.3) | 8.9 (5.6 to 13.8) | 1.8 (0.5 to 6.2) |
| ST2 Day 29 | 0.0 (0.0 to 11.7) | 2.6 (1.1 to 6.0) | 5.7 (3.2 to 9.9) | 0.8 (0.1 to 4.6) |
| ST2 Day 57 | 67.9 (49.3 to 82.1) | 72.3 (65.5 to 78.1) | 79.9 (73.7 to 84.9) | 1.7 (0.5 to 5.8) |
| ST2 Day 180 | 42.3 (25.5 to 61.1) | 66.1 (59.0 to 72.6) | 66.7 (59.7 to 73.0) | 0.9 (0.2 to 4.8) |
| ST2 Day 236 | 19.2 (8.5 to 37.9) | 42.6 (34.2 to 51.5) | 38.7 (30.4 to 47.6) | 0.0 (0.0 to 4.8) |
| ST2 Day 365 | 8.0 (2.2 to 25.0) | 15.3 (10.8 to 21.2) | 17.8 (13.0 to 23.8) | 0.9 (0.2 to 4.8) |
| ST3 Day 29 | 6.9 (1.9 to 22.0) | 4.2 (2.1 to 8.0) | 3.6 (1.8 to 7.3) | 1.7 (0.5 to 5.9) |
| ST3 Day 57 | 75.0 (56.6 to 87.3) | 80.1 (73.9 to 85.1) | 84.0 (78.2 to 88.5) | 2.5 (0.8 to 7.0) |
| ST3 Day 180 | 50.0 (32.1 to 67.9) | 68.9 (61.8 to 75.1) | 69.3 (62.4 to 75.4) | 1.8 (0.5 to 6.2) |
| ST3 Day 236 | 34.6 (19.4 to 53.8) | 39.3 (31.1 to 48.2) | 42.0 (33.5 to 51.0) | 2.6 (0.7 to 9.1) |
| ST3 Day 365 | 12.0 (4.2 to 30.0) | 17.5 (12.7 to 23.6) | 19.9 (14.9 to 26.1) | 1.8 (0.5 to 6.2) |
| ST4 Day 29 | 3.4 (0.6 to 17.2) | 2.6 (1.1 to 6.0) | 3.6 (1.8 to 7.3) | 0.8 (0.1 to 4.6) |
| ST4 Day 57 | 50.0 (32.6 to 67.4) | 58.6 (51.6 to 65.4) | 67.0 (60.1 to 73.2) | 0.8 (0.1 to 4.5) |
| ST4 Day 180 | 30.8 (16.5 to 50.0) | 57.4 (50.1 to 64.3) | 58.2 (51.1 to 65.0) | 0.9 (0.2 to 4.8) |
| ST4 Day 236 | 15.4 (6.2 to 33.5) | 36.1 (28.1 to 44.9) | 31.9 (24.2 to 40.8) | 1.3 (0.2 to 7.1) |
| ST4 Day 365 | 8.0 (2.2 to 25.0) | 19.7 (14.6 to 26.0) | 16.8 (12.1 to 22.7) | 2.7 (0.9 to 7.5) |
| ST5 Day 29 | 0.0 (0.0 to 11.7) | 1.6 (0.5 to 4.5) | 2.6 (1.1 to 5.9) | 0.0 (0.0 to 3.1) |
| ST5 Day 57 | 42.9 (26.5 to 60.9) | 58.1 (51.0 to 64.9) | 67.5 (60.7 to 73.7) | 0.0 (0.0 to 3.1) |
| ST5 Day 180 | 19.2 (8.5 to 37.9) | 49.7 (42.6 to 56.9) | 55.0 (47.9 to 61.9) | 0.9 (0.2 to 4.8) |
| ST5 Day 236 | 11.5 (4.0 to 29.0) | 32.0 (24.4 to 40.7) | 31.9 (24.2 to 40.8) | 1.3 (0.2 to 7.1) |
| ST5 Day 365 | 8.0 (2.2 to 25.0) | 13.1 (9.0 to 18.8) | 13.1 (9.0 to 18.6) | 0.9 (0.2 to 4.8) |
| ST6 Day 29 | 0.0 (0.0 to 11.7) | 6.3 (3.6 to 10.7) | 4.6 (2.5 to 8.6) | 1.7 (0.5 to 5.9) |
| ST6 Day 57 | 42.9 (26.5 to 60.9) | 54.5 (47.4 to 61.4) | 60.3 (53.3 to 66.9) | 1.7 (0.5 to 5.8) |
| ST6 Day 180 | 23.1 (11.0 to 42.1) | 54.1 (46.9 to 61.2) | 53.4 (46.3 to 60.4) | 2.6 (0.9 to 7.5) |
| ST6 Day 236 | 15.4 (6.2 to 33.5) | 35.2 (27.3 to 44.1) | 31.1 (23.5 to 39.9) | 3.9 (1.4 to 11.0) |
| ST6 Day 365 | 8.0 (2.2 to 25.0) | 16.9 (12.2 to 23.0) | 13.6 (9.5 to 19.2) | 3.5 (1.4 to 8.7) |
GMFR (Geometric Mean of the Fold Rise as compared to baseline) for IgG (Immunoglobulin G) against each OspA (Outer Surface Protein A) serotype (ST1 to ST6), determined by ELISA. Calculations are based on number of subjects with non-missing results.
| Geometric Mean of the Fold Rise | VLA15 Low Dose | VLA15 Medium Dose | VLA15 High Dose | Placebo |
|---|---|---|---|---|
| ST1 Day 29 | 1.0 (1.0 to 1.0) | 1.1 (1.0 to 1.1) | 1.1 (1.0 to 1.1) | 1.0 (1.0 to 1.0) |
| ST1 Day 57 | 1.6 (1.2 to 2.1) | 1.8 (1.6 to 2.1) | 2.0 (1.8 to 2.4) | 1.0 (1.0 to 1.0) |
| ST1 Day 180 | 1.3 (1.0 to 1.6) | 1.6 (1.4 to 1.8) | 1.7 (1.5 to 1.9) | 1.0 (1.0 to 1.0) |
| ST1 Day 236 | 1.1 (0.9 to 1.3) | 1.3 (1.1 to 1.4) | 1.3 (1.2 to 1.5) | 1.0 (1.0 to 1.1) |
| ST1 Day 365 | 1.0 (0.9 to 1.1) | 1.1 (1.1 to 1.2) | 1.1 (1.1 to 1.2) | 1.0 (1.0 to 1.1) |
| ST2 Day 29 | 1.0 (1.0 to 1.0) | 1.1 (1.0 to 1.1) | 1.1 (1.0 to 1.1) | 1.0 (1.0 to 1.0) |
| ST2 Day 57 | 3.2 (2.2 to 4.7) | 4.5 (3.8 to 5.2) | 5.4 (4.6 to 6.2) | 1.0 (1.0 to 1.1) |
| ST2 Day 180 | 1.9 (1.4 to 2.7) | 3.1 (2.7 to 3.6) | 3.3 (2.9 to 3.8) | 1.0 (1.0 to 1.0) |
| ST2 Day 236 | 1.2 (1.0 to 1.6) | 1.8 (1.6 to 2.1) | 1.8 (1.5 to 2.1) | 1.0 (1.0 to 1.0) |
| ST2 Day 365 | 1.1 (1.0 to 1.2) | 1.2 (1.1 to 1.3) | 1.2 (1.1 to 1.3) | 1.0 (1.0 to 1.0) |
| ST3 Day 29 | 1.1 (1.0 to 1.2) | 1.1 (1.0 to 1.1) | 1.1 (1.0 to 1.1) | 1.0 (1.0 to 1.1) |
| ST3 Day 57 | 5.0 (3.2 to 7.8) | 6.1 (5.1 to 7.2) | 7.2 (6.1 to 8.6) | 1.0 (1.0 to 1.1) |
| ST3 Day 180 | 2.4 (1.6 to 3.6) | 3.1 (2.7 to 3.5) | 3.4 (3.0 to 3.9) | 1.0 (1.0 to 1.1) |
| ST3 Day 236 | 1.6 (1.2 to 2.2) | 1.8 (1.5 to 2.0) | 1.9 (1.6 to 2.3) | 1.0 (1.0 to 1.1) |
| ST3 Day 365 | 1.2 (1.0 to 1.4) | 1.3 (1.2 to 1.4) | 1.3 (1.2 to 1.5) | 1.0 (1.0 to 1.1) |
| ST4 Day 29 | 1.0 (1.0 to 1.1) | 1.0 (1.0 to 1.1) | 1.1 (1.0 to 1.1) | 1.0 (1.0 to 1.0) |
| ST4 Day 57 | 2.1 (1.5 to 3.0) | 2.7 (2.4 to 3.2) | 3.2 (2.7 to 3.7) | 1.0 (1.0 to 1.0) |
| ST4 Day 180 | 1.5 (1.1 to 2.1) | 2.3 (2.0 to 2.6) | 2.4 (2.1 to 2.8) | 1.0 (1.0 to 1.0) |
| ST4 Day 236 | 1.2 (0.9 to 1.5) | 1.6 (1.4 to 1.8) | 1.6 (1.4 to 1.8) | 1.0 (1.0 to 1.1) |
| ST4 Day 365 | 1.1 (1.0 to 1.2) | 1.3 (1.2 to 1.4) | 1.3 (1.1 to 1.4) | 1.0 (1.0 to 1.1) |
| ST5 Day 29 | 1.0 (1.0 to 1.0) | 1.0 (1.0 to 1.1) | 1.0 (1.0 to 1.1) | 1.0 (1.0 to 1.0) |
| ST5 Day 57 | 2.1 (1.5 to 3.0) | 2.8 (2.4 to 3.2) | 3.6 (3.1 to 4.2) | 1.0 (1.0 to 1.0) |
| ST5 Day 180 | 1.3 (1.0 to 1.7) | 2.1 (1.9 to 2.4) | 2.5 (2.2 to 2.8) | 1.0 (1.0 to 1.0) |
| ST5 Day 236 | 1.1 (0.9 to 1.3) | 1.5 (1.4 to 1.7) | 1.6 (1.4 to 1.8) | 1.0 (1.0 to 1.0) |
| ST5 Day 365 | 1.1 (1.0 to 1.2) | 1.2 (1.1 to 1.2) | 1.2 (1.1 to 1.3) | 1.0 (1.0 to 1.0) |
| ST6 Day 29 | 1.0 (1.0 to 1.0) | 1.1 (1.0 to 1.1) | 1.1 (1.0 to 1.1) | 1.0 (1.0 to 1.0) |
| ST6 Day 57 | 2.0 (1.4 to 2.8) | 2.6 (2.3 to 3.0) | 3.1 (2.7 to 3.7) | 1.0 (1.0 to 1.0) |
| ST6 Day 180 | 1.4 (1.1 to 1.9) | 2.3 (2.0 to 2.6) | 2.5 (2.1 to 2.8) | 1.0 (1.0 to 1.1) |
| ST6 Day 236 | 1.2 (1.0 to 1.5) | 1.6 (1.4 to 1.8) | 1.6 (1.4 to 1.9) | 1.0 (1.0 to 1.1) |
| ST6 Day 365 | 1.1 (1.0 to 1.3) | 1.2 (1.1 to 1.3) | 1.2 (1.1 to 1.4) | 1.0 (1.0 to 1.1) |
GMTs (Geometric Mean Titers) for IgG (Immunoglobulin G) against each OspA (Outer Surface Protein A) serotype (ST1 to ST6), determined by ELISA, stratified by age group - Group 18 - 49 years. GMTs are calculated based on the number of subjects with non-missing results.
| U/mL | VLA15 Low Dose | VLA15 Medium Dose | VLA15 High Dose | Placebo |
|---|---|---|---|---|
| ST1 Day 1 | 20.8 (19.2 to 22.5) | 20.3 (19.7 to 21.0) | 20.3 (19.7 to 20.8) | 22.0 (19.6 to 24.6) |
| ST1 Day 29 | 21.1 (18.9 to 23.5) | 20.9 (19.7 to 22.1) | 21.4 (19.9 to 23.0) | 22.0 (19.6 to 24.6) |
| ST1 Day 57 | 32.7 (25.1 to 42.6) | 34.8 (30.0 to 40.3) | 43.6 (36.5 to 52.0) | 22.4 (19.9 to 25.2) |
| ST1 Day 85 | 74.3 (46.4 to 119.0) | 105.2 (88.8 to 124.5) | 129.6 (107.6 to 156.2) | 21.9 (19.6 to 24.5) |
| ST1 Day 180 | 26.2 (19.9 to 34.5) | 31.7 (27.5 to 36.4) | 34.7 (29.7 to 40.5) | 21.0 (19.5 to 22.7) |
| ST1 Day 236 | 22.2 (18.8 to 26.1) | 26.1 (22.5 to 30.3) | 26.4 (22.4 to 31.2) | 21.7 (19.3 to 24.4) |
| ST1 Day 365 | 20.9 (19.1 to 22.9) | 23.0 (21.1 to 25.1) | 23.8 (21.4 to 26.5) | 21.7 (19.7 to 23.9) |
| ST2 Day 1 | 21.3 (18.7 to 24.2) | 20.0 (20.0 to 20.0) | 20.1 (19.9 to 20.3) | 21.0 (19.6 to 22.5) |
| ST2 Day 29 | 21.1 (18.9 to 23.7) | 20.7 (19.9 to 21.5) | 21.4 (20.5 to 22.3) | 21.0 (19.6 to 22.4) |
| ST2 Day 57 | 69.0 (47.7 to 99.8) | 89.5 (74.2 to 107.9) | 121.4 (102.4 to 143.9) | 21.4 (19.8 to 23.2) |
| ST2 Day 85 | 180.9 (124.8 to 262.3) | 296.5 (258.6 to 339.9) | 322.1 (277.1 to 374.4) | 21.2 (19.8 to 22.7) |
| ST2 Day 180 | 41.2 (29.3 to 57.9) | 64.5 (54.7 to 76.0) | 71.8 (60.8 to 84.7) | 20.5 (19.5 to 21.6) |
| ST2 Day 236 | 26.6 (21.2 to 33.4) | 39.6 (33.5 to 46.8) | 37.0 (31.2 to 43.9) | 20.6 (19.4 to 22.0) |
| ST2 Day 365 | 21.8 (19.2 to 24.7) | 24.5 (22.4 to 26.8) | 25.1 (23.0 to 27.4) | 20.5 (19.5 to 21.6) |
| ST3 Day 1 | 21.9 (19.1 to 25.1) | 20.3 (19.9 to 20.7) | 20.2 (19.8 to 20.5) | 20.6 (19.5 to 21.7) |
| ST3 Day 29 | 23.7 (20.0 to 28.0) | 21.0 (20.1 to 21.9) | 21.7 (20.5 to 23.0) | 20.7 (19.6 to 21.9) |
| ST3 Day 57 | 110.2 (71.1 to 171.0) | 122.6 (101.3 to 148.3) | 159.4 (130.1 to 195.2) | 21.3 (19.7 to 22.9) |
| ST3 Day 85 | 267.4 (194.8 to 367.1) | 295.1 (255.6 to 340.8) | 334.2 (282.1 to 395.9) | 20.7 (19.6 to 21.8) |
| ST3 Day 180 | 53.1 (35.6 to 79.1) | 60.7 (51.7 to 71.2) | 73.0 (61.3 to 86.9) | 20.0 (20.0 to 20.0) |
| ST3 Day 236 | 35.3 (25.7 to 48.6) | 35.8 (30.4 to 42.2) | 39.9 (33.0 to 48.3) | 20.2 (19.8 to 20.7) |
| ST3 Day 365 | 25.2 (19.9 to 31.8) | 25.4 (23.2 to 27.8) | 28.0 (24.7 to 31.8) | 20.2 (19.8 to 20.7) |
| ST4 Day 1 | 21.4 (18.7 to 24.4) | 20.8 (20.0 to 21.6) | 20.3 (19.9 to 20.8) | 22.0 (20.2 to 24.0) |
| ST4 Day 29 | 22.1 (19.1 to 25.6) | 21.5 (20.4 to 22.8) | 21.5 (20.3 to 22.8) | 22.3 (20.4 to 24.4) |
| ST4 Day 57 | 45.9 (32.8 to 64.2) | 56.9 (48.3 to 67.1) | 71.4 (59.1 to 86.3) | 22.4 (20.4 to 24.6) |
| ST4 Day 85 | 117.0 (76.6 to 178.7) | 177.1 (154.5 to 203.1) | 206.8 (175.0 to 244.3) | 22.1 (20.3 to 24.1) |
| ST4 Day 180 | 32.8 (24.1 to 44.6) | 48.2 (41.8 to 55.6) | 53.2 (44.9 to 63.0) | 21.7 (20.0 to 23.5) |
| ST4 Day 236 | 25.5 (20.6 to 31.5) | 34.9 (29.9 to 40.8) | 33.6 (28.1 to 40.1) | 21.2 (19.5 to 23.2) |
| ST4 Day 365 | 21.8 (19.2 to 24.7) | 26.7 (24.2 to 29.5) | 26.7 (23.5 to 30.3) | 21.4 (19.9 to 23.0) |
| ST5 Day 1 | 20.6 (19.4 to 21.8) | 20.4 (19.9 to 20.9) | 20.2 (19.8 to 20.8) | 21.5 (20.0 to 23.1) |
| ST5 Day 29 | 20.7 (19.2 to 22.4) | 20.6 (19.9 to 21.3) | 21.1 (20.1 to 22.1) | 21.4 (20.0 to 22.9) |
| ST5 Day 57 | 42.7 (29.8 to 61.3) | 56.6 (47.8 to 67.0) | 80.7 (66.3 to 98.1) | 21.6 (20.0 to 23.3) |
| ST5 Day 85 | 118.3 (78.3 to 178.9) | 180.7 (156.8 to 208.2) | 218.3 (183.6 to 259.7) | 21.4 (20.0 to 22.9) |
| ST5 Day 180 | 26.7 (20.7 to 34.3) | 42.5 (36.7 to 49.1) | 54.6 (45.9 to 64.8) | 20.8 (19.7 to 21.9) |
| ST5 Day 236 | 23.0 (19.6 to 27.0) | 31.9 (27.5 to 37.1) | 33.4 (27.7 to 40.2) | 21.0 (19.6 to 22.6) |
| ST5 Day 365 | 21.7 (19.3 to 24.3) | 24.0 (22.2 to 26.0) | 26.0 (23.0 to 29.5) | 20.8 (19.7 to 21.9) |
| ST6 Day 1 | 21.1 (18.9 to 23.5) | 20.8 (20.0 to 21.5) | 21.2 (20.1 to 22.4) | 21.7 (20.0 to 23.6) |
| ST6 Day 29 | 21.1 (18.9 to 23.6) | 22.3 (21.0 to 23.7) | 22.2 (20.8 to 23.7) | 22.1 (20.3 to 24.0) |
| ST6 Day 57 | 42.3 (29.8 to 60.1) | 54.5 (46.2 to 64.3) | 72.3 (59.2 to 88.3) | 22.3 (20.3 to 24.4) |
| ST6 Day 85 | 115.6 (76.5 to 174.7) | 185.8 (162.2 to 213.0) | 225.6 (191.9 to 265.3) | 21.8 (20.1 to 23.7) |
| ST6 Day 180 | 30.1 (22.6 to 40.2) | 46.7 (40.4 to 53.9) | 54.2 (45.5 to 64.4) | 20.6 (19.7 to 21.4) |
| ST6 Day 236 | 25.6 (20.7 to 31.8) | 34.6 (29.8 to 40.2) | 34.6 (28.7 to 41.9) | 21.4 (19.7 to 23.2) |
| ST6 Day 365 | 22.1 (19.2 to 25.5) | 25.5 (23.3 to 27.9) | 27.7 (24.3 to 31.6) | 21.4 (20.1 to 22.7) |
GMTs (Geometric Mean Titers) for IgG (Immunoglobulin G) Against Each OspA (Outer Surface Protein A) Serotype (ST1 to ST6), determined by ELISA, stratified by age group - Group 50 - 65 years. GMTs are calculated based on the number of subjects with non-missing results.
| U/mL | VLA15 Low Dose | VLA15 Medium Dose | VLA15 High Dose | Placebo |
|---|---|---|---|---|
| ST1 Day 1 | — | 21.0 (19.0 to 23.3) | 20.0 (20.0 to 20.0) | 20.6 (19.4 to 22.0) |
| ST1 Day 29 | — | 24.2 (18.7 to 31.4) | 20.9 (19.5 to 22.5) | 21.0 (19.6 to 22.6) |
| ST1 Day 57 | — | 44.5 (31.7 to 62.3) | 36.2 (28.6 to 45.8) | 20.5 (19.5 to 21.6) |
| ST1 Day 85 | — | 95.3 (67.2 to 135.1) | 89.2 (66.0 to 120.4) | 21.2 (19.5 to 23.1) |
| ST1 Day 180 | — | 35.4 (26.8 to 46.9) | 32.1 (26.4 to 39.0) | 21.0 (19.6 to 22.5) |
| ST1 Day 236 | — | 24.5 (20.4 to 29.4) | 25.6 (21.4 to 30.5) | 20.9 (19.1 to 22.9) |
| ST1 Day 365 | — | 24.3 (19.6 to 30.1) | 21.4 (19.6 to 23.2) | 20.5 (19.4 to 21.7) |
| ST2 Day 1 | — | 20.0 (20.0 to 20.0) | 20.0 (20.0 to 20.0) | 20.0 (20.0 to 20.0) |
| ST2 Day 29 | — | 22.0 (18.9 to 25.7) | 21.6 (19.4 to 24.0) | 20.9 (19.1 to 22.8) |
| ST2 Day 57 | — | 88.7 (64.1 to 122.5) | 81.5 (60.4 to 110.2) | 20.9 (19.1 to 22.8) |
| ST2 Day 85 | — | 245.5 (190.3 to 316.6) | 265.0 (204.2 to 344.0) | 20.8 (19.2 to 22.4) |
| ST2 Day 180 | — | 58.5 (45.4 to 75.3) | 57.4 (44.1 to 74.5) | 20.8 (19.2 to 22.4) |
| ST2 Day 236 | — | 30.5 (24.1 to 38.7) | 32.7 (24.8 to 43.1) | 20.0 (20.0 to 20.0) |
| ST2 Day 365 | — | 24.9 (21.3 to 29.2) | 24.1 (21.3 to 27.3) | 20.9 (19.1 to 22.7) |
| ST3 Day 1 | — | 20.7 (19.7 to 21.7) | 20.0 (20.0 to 20.0) | 20.0 (20.0 to 20.0) |
| ST3 Day 29 | — | 23.3 (18.9 to 28.7) | 20.0 (20.0 to 20.0) | 21.2 (18.8 to 23.8) |
| ST3 Day 57 | — | 126.7 (88.0 to 182.4) | 118.3 (85.7 to 163.1) | 21.1 (18.9 to 23.6) |
| ST3 Day 85 | — | 258.9 (194.9 to 343.8) | 256.5 (193.5 to 340.0) | 21.1 (19.0 to 23.4) |
| ST3 Day 180 | — | 68.8 (53.5 to 88.4) | 59.7 (46.4 to 76.7) | 21.9 (19.1 to 25.0) |
| ST3 Day 236 | — | 35.7 (27.3 to 46.8) | 36.9 (27.2 to 50.1) | 22.0 (18.0 to 26.9) |
| ST3 Day 365 | — | 26.0 (21.5 to 31.5) | 24.8 (21.6 to 28.4) | 21.3 (18.7 to 24.2) |
| ST4 Day 1 | — | 21.3 (19.8 to 23.0) | 20.0 (20.0 to 20.0) | 20.9 (19.1 to 22.9) |
| ST4 Day 29 | — | 22.9 (18.7 to 28.0) | 21.0 (19.4 to 22.8) | 21.2 (18.8 to 23.8) |
| ST4 Day 57 | — | 58.6 (42.6 to 80.6) | 51.4 (39.8 to 66.4) | 21.2 (18.8 to 23.9) |
| ST4 Day 85 | — | 158.2 (119.5 to 209.4) | 158.1 (122.5 to 203.9) | 21.1 (18.9 to 23.4) |
| ST4 Day 180 | — | 48.0 (37.5 to 61.5) | 41.3 (33.6 to 50.9) | 21.1 (18.9 to 23.6) |
| ST4 Day 236 | — | 28.0 (23.1 to 33.8) | 28.0 (22.7 to 34.7) | 23.1 (18.7 to 28.5) |
| ST4 Day 365 | — | 26.0 (21.7 to 31.1) | 22.9 (20.9 to 25.1) | 22.5 (19.4 to 26.1) |
| ST5 Day 1 | — | 21.4 (19.8 to 23.0) | 20.0 (20.0 to 20.0) | 21.0 (19.0 to 23.4) |
| ST5 Day 29 | — | 22.7 (19.0 to 27.1) | 20.8 (19.2 to 22.6) | 21.3 (18.7 to 24.3) |
| ST5 Day 57 | — | 61.0 (44.9 to 82.9) | 55.7 (42.5 to 72.8) | 21.3 (18.7 to 24.2) |
| ST5 Day 85 | — | 166.4 (124.1 to 223.0) | 162.1 (124.0 to 211.9) | 21.2 (18.8 to 23.9) |
| ST5 Day 180 | — | 47.4 (37.2 to 60.5) | 40.8 (32.6 to 51.1) | 21.9 (19.1 to 25.2) |
| ST5 Day 236 | — | 28.8 (23.4 to 35.6) | 30.2 (24.1 to 37.7) | 23.1 (18.6 to 28.7) |
| ST5 Day 365 | — | 23.9 (20.5 to 27.8) | 22.4 (20.2 to 24.7) | 21.9 (19.1 to 25.2) |
| ST6 Day 1 | — | 22.6 (20.3 to 25.1) | 20.0 (20.0 to 20.0) | 21.4 (18.7 to 24.4) |
| ST6 Day 29 | — | 23.6 (19.9 to 28.1) | 21.6 (19.6 to 23.9) | 21.7 (18.3 to 25.8) |
| ST6 Day 57 | — | 58.0 (43.2 to 77.7) | 51.4 (39.3 to 67.1) | 21.7 (18.4 to 25.6) |
| ST6 Day 85 | — | 178.7 (136.2 to 236.3) | 174.3 (133.9 to 226.9) | 21.6 (18.5 to 25.3) |
| ST6 Day 180 | — | 52.3 (41.1 to 66.5) | 45.5 (36.1 to 57.3) | 23.6 (19.2 to 28.8) |
| ST6 Day 236 | — | 30.3 (24.1 to 38.1) | 30.1 (23.6 to 38.3) | 24.6 (18.0 to 33.6) |
| ST6 Day 365 | — | 26.2 (22.2 to 30.9) | 22.5 (20.2 to 25.0) | 22.8 (18.7 to 27.8) |
SCRs (Seroconversion Rate) for Seroconversion for ELISA is defined as: * for subjects that are seronegative at Visit 1 (baseline): a change from seronegative at Visit 1 to seropositive (i.e. antibody titer of ≥40 U/mL) at a vertain time point. * for subjects that are seropositive at Visit 1 (baseline): a ≥ 4-fold rise in IgG antibody titer from Visit 1. Percentages are based on the number of subjects with non-missing observations.
| percentage of subjects | VLA15 Low Dose | VLA15 Medium Dose | VLA15 High Dose | Placebo |
|---|---|---|---|---|
| ST1 Day 29 | 0.0 (0.0 to 11.7) | 2.3 (0.8 to 6.4) | 2.9 (1.1 to 7.3) | 0.0 (0.0 to 4.2) |
| ST1 Day 57 | 39.3 (23.6 to 57.6) | 36.1 (28.4 to 44.5) | 43.4 (35.3 to 51.8) | 1.1 (0.2 to 6.2) |
| ST1 Day 85 | 65.4 (46.2 to 80.6) | 85.9 (78.9 to 90.9) | 85.6 (78.6 to 90.6) | 0.0 (0.0 to 4.3) |
| ST1 Day 180 | 11.5 (4.0 to 29.0) | 31.2 (23.7 to 39.8) | 36.4 (28.7 to 44.8) | 0.0 (0.0 to 4.5) |
| ST1 Day 236 | 7.7 (2.1 to 24.1) | 18.2 (11.5 to 27.5) | 17.9 (11.1 to 27.4) | 1.7 (0.3 to 9.1) |
| ST1 Day 365 | 4.0 (0.7 to 19.5) | 11.3 (6.8 to 18.1) | 10.5 (6.4 to 16.9) | 1.2 (0.2 to 6.6) |
| ST2 Day 29 | 0.0 (0.0 to 11.7) | 2.3 (0.8 to 6.4) | 6.6 (3.5 to 12.1) | 0.0 (0.0 to 4.2) |
| ST2 Day 57 | 67.9 (49.3 to 82.1) | 72.9 (64.8 to 79.8) | 85.3 (78.4 to 90.3) | 1.1 (0.2 to 6.2) |
| ST2 Day 85 | 88.5 (71.0 to 96.0) | 100 (97.1 to 100) | 96.2 (91.4 to 98.4) | 1.2 (0.2 to 6.4) |
| ST2 Day 180 | 42.3 (25.5 to 61.1) | 68.0 (59.4 to 75.5) | 69.7 (61.4 to 76.9) | 0.0 (0.0 to 4.5) |
| ST2 Day 236 | 19.2 (8.5 to 37.9) | 47.7 (37.6 to 58.0) | 41.7 (31.7 to 52.3) | 0.0 (0.0 to 6.2) |
| ST2 Day 365 | 8.0 (2.2 to 25.0) | 15.3 (10.0 to 22.7) | 18.8 (13.1 to 26.3) | 0.0 (0.0 to 4.5) |
| ST3 Day 29 | 6.9 (1.9 to 22.0) | 3.0 (1.2 to 7.5) | 5.1 (2.5 to 10.2) | 1.1 (0.2 to 6.2) |
| ST3 Day 57 | 75.0 (56.6 to 87.3) | 81.2 (73.7 to 86.9) | 85.3 (78.4 to 90.3) | 2.3 (0.6 to 7.9) |
| ST3 Day 85 | 96.2 (81.1 to 99.3) | 98.4 (94.5 to 99.6) | 97.0 (92.5 to 98.8) | 1.2 (0.2 to 6.4) |
| ST3 Day 180 | 50.0 (32.1 to 67.9) | 66.4 (57.7 to 74.1) | 70.5 (62.2 to 77.6) | 0.0 (0.0 to 4.5) |
| ST3 Day 236 | 34.6 (19.4 to 53.8) | 39.8 (30.2 to 50.2) | 44.0 (33.9 to 54.7) | 1.7 (0.3 to 9.1) |
| ST3 Day 365 | 12.0 (4.2 to 30.0) | 19.4 (13.4 to 27.2) | 21.8 (15.6 to 29.6) | 1.2 (0.2 to 6.6) |
| ST4 Day 29 | 3.4 (0.6 to 17.2) | 2.3 (0.8 to 6.5) | 3.7 (1.6 to 8.3) | 1.1 (0.2 to 6.2) |
| ST4 Day 57 | 50.0 (32.6 to 67.4) | 60.2 (51.7 to 68.1) | 71.3 (63.2 to 78.3) | 1.1 (0.2 to 6.2) |
| ST4 Day 85 | 80.8 (62.1 to 91.5) | 96.1 (91.2 to 98.3) | 94.7 (89.5 to 97.4) | 1.2 (0.2 to 6.4) |
| ST4 Day 180 | 30.8 (16.5 to 50.0) | 58.4 (49.6 to 66.7) | 60.6 (52.1 to 68.5) | 1.2 (0.2 to 6.6) |
| ST4 Day 236 | 15.4 (6.2 to 33.5) | 38.6 (29.1 to 49.1) | 34.5 (25.2 to 45.2) | 0.0 (0.0 to 6.2) |
| ST4 Day 365 | 8.0 (2.2 to 25.0) | 21.0 (14.7 to 29.0) | 18.0 (12.4 to 25.4) | 1.2 (0.2 to 6.6) |
| ST5 Day 29 | 0.0 (0.0 to 11.7) | 0.8 (0.1 to 4.1) | 2.9 (1.1 to 7.3) | 0.0 (0.0 to 4.2) |
| ST5 Day 57 | 42.9 (26.5 to 60.9) | 59.4 (50.9 to 67.4) | 72.8 (64.8 to 79.6) | 0.0 (0.0 to 4.2) |
| ST5 Day 85 | 80.8 (62.1 to 91.5) | 94.5 (89.1 to 97.3) | 91.7 (85.7 to 95.3) | 0.0 (0.0 to 4.3) |
| ST5 Day 180 | 19.2 (8.5 to 37.9) | 48.8 (40.2 to 57.5) | 59.1 (50.6 to 67.1) | 0.0 (0.0 to 4.5) |
| ST5 Day 236 | 11.5 (4.0 to 29.0) | 33.0 (24.0 to 43.3) | 32.1 (23.1 to 42.7) | 0.0 (0.0 to 6.2) |
| ST5 Day 365 | 8.0 (2.2 to 25.0) | 15.3 (10.0 to 22.7) | 15.0 (10.0 to 22.1) | 0.0 (0.0 to 4.5) |
| ST6 Day 29 | 0.0 (0.0 to 11.7) | 6.8 (3.6 to 12.4) | 4.4 (2.0 to 9.3) | 2.3 (0.6 to 7.9) |
| ST6 Day 57 | 42.9 (26.5 to 60.9) | 55.6 (47.2 to 63.8) | 64.0 (55.6 to 71.6) | 2.3 (0.6 to 7.9) |
| ST6 Day 85 | 80.8 (62.1 to 91.5) | 95.3 (90.2 to 97.8) | 92.4 (86.6 to 95.8) | 1.2 (0.2 to 6.4) |
| ST6 Day 180 | 23.1 (11.0 to 42.1) | 54.4 (45.7 to 62.9) | 53.8 (45.3 to 62.1) | 1.2 (0.2 to 6.6) |
| ST6 Day 236 | 15.4 (6.2 to 33.5) | 38.6 (29.1 to 49.1) | 32.1 (23.1 to 42.7) | 3.4 (1.0 to 11.7) |
| ST6 Day 365 | 8.0 (2.2 to 25.0) | 17.7 (12.0 to 25.4) | 15.8 (10.6 to 22.9) | 3.7 (1.3 to 10.2) |
Seroconversion for ELISA is defined as: * for subjects that are seronegative at Visit 1 (baseline): a change from seronegative at Visit 1 to seropositive (i.e. antibody titer of ≥40 U/mL) at a vertain time point. * for subjects that are seropositive at Visit 1 (baseline): a ≥ 4-fold rise in IgG antibody titer from Visit 1. Percentages are based on the number of subjects with non-missing observations.
| percentage of subjects | VLA15 Low Dose | VLA15 Medium Dose | VLA15 High Dose | Placebo |
|---|---|---|---|---|
| ST1 Day 29 | — | 6.9 (2.7 to 16.4) | 3.4 (1.0 to 11.7) | 3.1 (0.6 to 15.7) |
| ST1 Day 57 | — | 39.7 (28.1 to 52.5) | 34.5 (23.6 to 47.3) | 3.0 (0.5 to 15.3) |
| ST1 Day 85 | — | 71.2 (58.6 to 81.2) | 71.9 (59.2 to 81.9) | 3.0 (0.5 to 15.3) |
| ST1 Day 180 | — | 36.2 (25.1 to 49.1) | 33.3 (22.5 to 46.3) | 3.1 (0.6 to 15.7) |
| ST1 Day 236 | — | 14.7 (6.4 to 30.1) | 20.0 (10.0 to 35.9) | 5.6 (1.0 to 25.8) |
| ST1 Day 365 | — | 10.2 (4.7 to 20.5) | 5.2 (1.8 to 14.1) | 3.2 (0.6 to 16.2) |
| ST2 Day 29 | — | 3.4 (1.0 to 11.7) | 3.4 (1.0 to 11.7) | 3.1 (0.6 to 15.7) |
| ST2 Day 57 | — | 70.7 (58.0 to 80.8) | 67.2 (54.4 to 77.9) | 3.0 (0.5 to 15.3) |
| ST2 Day 85 | — | 94.9 (86.1 to 98.3) | 93.0 (83.3 to 97.2) | 3.0 (0.5 to 15.3) |
| ST2 Day 180 | — | 62.1 (49.2 to 73.4) | 59.6 (46.7 to 71.4) | 3.1 (0.6 to 15.7) |
| ST2 Day 236 | — | 29.4 (16.8 to 46.2) | 31.4 (18.6 to 48.0) | 0.0 (0.0 to 17.6) |
| ST2 Day 365 | — | 15.3 (8.2 to 26.5) | 15.5 (8.4 to 26.9) | 3.2 (0.6 to 16.2) |
| ST3 Day 29 | — | 6.9 (2.7 to 16.4) | 0.0 (0.0 to 6.2) | 3.1 (0.6 to 15.7) |
| ST3 Day 57 | — | 77.6 (65.3 to 86.4) | 81.0 (69.1 to 89.1) | 3.0 (0.5 to 15.3) |
| ST3 Day 85 | — | 94.9 (86.1 to 98.3) | 93.0 (83.3 to 97.2) | 3.0 (0.5 to 15.3) |
| ST3 Day 180 | — | 74.1 (61.6 to 83.7) | 66.7 (53.7 to 77.5) | 6.3 (1.7 to 20.1) |
| ST3 Day 236 | — | 38.2 (23.9 to 55.0) | 37.1 (23.2 to 53.7) | 5.6 (1.0 to 25.8) |
| ST3 Day 365 | — | 13.6 (7.0 to 24.5) | 15.5 (8.4 to 26.9) | 3.2 (0.6 to 16.2) |
| ST4 Day 29 | — | 3.4 (1.0 to 11.7) | 3.4 (1.0 to 11.7) | 0.0 (0.0 to 10.7) |
| ST4 Day 57 | — | 55.2 (42.5 to 67.3) | 56.9 (44.1 to 68.8) | 0.0 (0.0 to 10.4) |
| ST4 Day 85 | — | 89.8 (79.5 to 95.3) | 91.2 (81.1 to 96.2) | 0.0 (0.0 to 10.4) |
| ST4 Day 180 | — | 55.2 (42.5 to 67.3) | 52.6 (39.9 to 65.0) | 0.0 (0.0 to 10.7) |
| ST4 Day 236 | — | 29.4 (16.8 to 46.2) | 25.7 (14.2 to 42.1) | 5.6 (1.0 to 25.8) |
| ST4 Day 365 | — | 16.9 (9.5 to 28.5) | 13.8 (7.2 to 24.9) | 6.5 (1.8 to 20.7) |
| ST5 Day 29 | — | 3.4 (1.0 to 11.7) | 1.7 (0.3 to 9.1) | 0.0 (0.0 to 10.7) |
| ST5 Day 57 | — | 55.2 (42.5 to 67.3) | 55.2 (42.5 to 67.3) | 0.0 (0.0 to 10.4) |
| ST5 Day 85 | — | 84.7 (73.5 to 91.8) | 87.7 (76.8 to 93.9) | 0.0 (0.0 to 10.4) |
| ST5 Day 180 | — | 51.7 (39.2 to 64.1) | 45.6 (33.4 to 58.4) | 3.1 (0.6 to 15.7) |
| ST5 Day 236 | — | 29.4 (16.8 to 46.2) | 31.4 (18.6 to 48.0) | 5.6 (1.0 to 25.8) |
| ST5 Day 365 | — | 8.5 (3.7 to 18.4) | 8.6 (3.7 to 18.6) | 3.2 (0.6 to 16.2) |
| ST6 Day 29 | — | 5.2 (1.8 to 14.1) | 5.2 (1.8 to 14.1) | 0.0 (0.0 to 10.7) |
| ST6 Day 57 | — | 51.7 (39.2 to 64.1) | 51.7 (39.2 to 64.1) | 0.0 (0.0 to 10.4) |
| ST6 Day 85 | — | 88.1 (77.5 to 94.1) | 89.5 (78.9 to 95.1) | 0.0 (0.0 to 10.4) |
| ST6 Day 180 | — | 53.4 (40.8 to 65.7) | 52.6 (39.9 to 65.0) | 6.3 (1.7 to 20.1) |
| ST6 Day 236 | — | 26.5 (14.6 to 43.1) | 28.6 (16.3 to 45.1) | 5.6 (1.0 to 25.8) |
| ST6 Day 365 | — | 15.3 (8.2 to 26.5) | 8.6 (3.7 to 18.6) | 3.2 (0.6 to 16.2) |
GMFRs (Geometric Mean of the Fold Rise as Compared to Baseline) for IgG (Immunoglobulin G) Against Each OspA (Outer Surface Protein A) Serotype (ST1 to ST6), stratified by age group - Group 18 - 49 years. Calculations are based on number of subjects with non-missing results.
| Geometric Mean of the Fold Rise | VLA15 Low Dose | VLA15 Medium Dose | VLA15 High Dose | Placebo |
|---|---|---|---|---|
| ST1 Day 29 | 1.0 (1.0 to 1.0) | 1.0 (1.0 to 1.1) | 1.1 (1.0 to 1.1) | 1.0 (1.0 to 1.0) |
| ST1 Day 57 | 1.6 (1.2 to 2.1) | 1.7 (1.5 to 2.0) | 2.2 (1.8 to 2.6) | 1.0 (1.0 to 1.1) |
| ST1 Day 85 | 3.6 (2.2 to 5.6) | 5.3 (4.4 to 6.2) | 6.4 (5.3 to 7.7) | 1.0 (1.0 to 1.0) |
| ST1 Day 180 | 1.3 (1.0 to 1.6) | 1.6 (1.4 to 1.8) | 1.7 (1.5 to 2.0) | 1.0 (1.0 to 1.0) |
| ST1 Day 236 | 1.1 (0.9 to 1.3) | 1.3 (1.1 to 1.4) | 1.3 (1.1 to 1.6) | 1.0 (1.0 to 1.1) |
| ST1 Day 365 | 1.0 (0.9 to 1.1) | 1.1 (1.1 to 1.2) | 1.2 (1.1 to 1.3) | 1.0 (1.0 to 1.1) |
| ST2 Day 29 | 1.0 (1.0 to 1.0) | 1.0 (1.0 to 1.1) | 1.1 (1.0 to 1.1) | 1.0 (1.0 to 1.0) |
| ST2 Day 57 | 3.2 (2.2 to 4.7) | 4.5 (3.7 to 5.4) | 6.0 (5.1 to 7.2) | 1.0 (1.0 to 1.1) |
| ST2 Day 85 | 8.4 (5.7 to 12.4) | 14.8 (12.9 to 17.0) | 16.0 (13.8 to 18.6) | 1.0 (1.0 to 1.0) |
| ST2 Day 180 | 1.9 (1.4 to 2.7) | 3.2 (2.7 to 3.8) | 3.6 (3.0 to 4.2) | 1.0 (1.0 to 1.0) |
| ST2 Day 236 | 1.2 (1.0 to 1.6) | 2.0 (1.7 to 2.3) | 1.8 (1.5 to 2.2) | 1.0 (1.0 to 1.0) |
| ST2 Day 365 | 1.1 (1.0 to 1.2) | 1.2 (1.1 to 1.3) | 1.2 (1.1 to 1.4) | 1.0 (1.0 to 1.0) |
| ST3 Day 29 | 1.1 (1.0 to 1.2) | 1.0 (1.0 to 1.1) | 1.1 (1.0 to 1.1) | 1.0 (1.0 to 1.0) |
| ST3 Day 57 | 5.0 (3.2 to 7.8) | 6.0 (5.0 to 7.3) | 7.9 (6.4 to 9.7) | 1.0 (1.0 to 1.1) |
| ST3 Day 85 | 12.1 (8.6 to 17.0) | 14.7 (12.7 to 16.9) | 16.6 (14.0 to 19.6) | 1.0 (1.0 to 1.0) |
| ST3 Day 180 | 2.4 (1.6 to 3.6) | 3.0 (2.6 to 3.5) | 3.6 (3.0 to 4.3) | 1.0 (1.0 to 1.0) |
| ST3 Day 236 | 1.6 (1.2 to 2.2) | 1.8 (1.5 to 2.1) | 2.0 (1.6 to 2.4) | 1.0 (1.0 to 1.0) |
| ST3 Day 365 | 1.2 (1.0 to 1.4) | 1.3 (1.2 to 1.4) | 1.4 (1.2 to 1.6) | 1.0 (1.0 to 1.0) |
| ST4 Day 29 | 1.0 (1.0 to 1.1) | 1.0 (1.0 to 1.1) | 1.1 (1.0 to 1.1) | 1.0 (1.0 to 1.0) |
| ST4 Day 57 | 2.1 (1.5 to 3.0) | 2.7 (2.3 to 3.2) | 3.5 (2.9 to 4.2) | 1.0 (1.0 to 1.0) |
| ST4 Day 85 | 5.4 (3.5 to 8.5) | 8.6 (7.5 to 9.8) | 10.2 (8.6 to 12.0) | 1.0 (1.0 to 1.0) |
| ST4 Day 180 | 1.5 (1.1 to 2.1) | 2.3 (2.0 to 2.7) | 2.6 (2.2 to 3.1) | 1.0 (1.0 to 1.1) |
| ST4 Day 236 | 1.2 (0.9 to 1.5) | 1.7 (1.4 to 2.0) | 1.7 (1.4 to 2.0) | 1.0 (1.0 to 1.0) |
| ST4 Day 365 | 1.1 (1.0 to 1.2) | 1.3 (1.2 to 1.4) | 1.3 (1.2 to 1.5) | 1.0 (1.0 to 1.0) |
| ST5 Day 29 | 1.0 (1.0 to 1.0) | 1.0 (1.0 to 1.0) | 1.0 (1.0 to 1.1) | 1.0 (1.0 to 1.0) |
| ST5 Day 57 | 2.1 (1.5 to 3.0) | 2.8 (2.4 to 3.3) | 4.0 (3.3 to 4.8) | 1.0 (1.0 to 1.0) |
| ST5 Day 85 | 5.7 (3.8 to 8.7) | 9.0 (7.8 to 10.3) | 10.8 (9.1 to 12.8) | 1.0 (1.0 to 1.0) |
| ST5 Day 180 | 1.3 (1.0 to 1.7) | 2.1 (1.8 to 2.4) | 2.7 (2.3 to 3.2) | 1.0 (1.0 to 1.0) |
| ST5 Day 236 | 1.1 (0.9 to 1.3) | 1.6 (1.4 to 1.8) | 1.6 (1.4 to 2.0) | 1.0 (1.0 to 1.0) |
| ST5 Day 365 | 1.1 (1.0 to 1.2) | 1.2 (1.1 to 1.3) | 1.3 (1.1 to 1.4) | 1.0 (1.0 to 1.0) |
| ST6 Day 29 | 1.0 (1.0 to 1.0) | 1.1 (1.0 to 1.1) | 1.0 (1.0 to 1.1) | 1.0 (1.0 to 1.0) |
| ST6 Day 57 | 2.0 (1.4 to 2.8) | 2.6 (2.2 to 3.1) | 3.4 (2.8 to 4.2) | 1.0 (1.0 to 1.1) |
| ST6 Day 85 | 5.4 (3.6 to 8.3) | 9.1 (7.9 to 10.4) | 10.6 (9.0 to 12.5) | 1.0 (1.0 to 1.0) |
| ST6 Day 180 | 1.4 (1.1 to 1.9) | 2.3 (2.0 to 2.6) | 2.5 (2.2 to 3.0) | 1.0 (1.0 to 1.0) |
| ST6 Day 236 | 1.2 (1.0 to 1.5) | 1.7 (1.5 to 2.0) | 1.7 (1.4 to 2.0) | 1.0 (1.0 to 1.1) |
| ST6 Day 365 | 1.1 (1.0 to 1.3) | 1.2 (1.1 to 1.4) | 1.3 (1.2 to 1.5) | 1.0 (1.0 to 1.1) |
GMFRs (Geometric Mean of the Fold Rise as Compared to Baseline) for IgG (Immunoglobulin G) Against Each OspA (Outer Surface Protein A) Serotype (ST1 to ST6), stratified by age group - Group 50 - 65 years. Calculations are based on number of subjects with non-missing results.
| Geometric Mean of the Fold Rise | VLA15 Low Dose | VLA15 Medium Dose | VLA15 High Dose | Placebo |
|---|---|---|---|---|
| ST1 Day 29 | — | 1.2 (1.0 to 1.4) | 1.0 (1.0 to 1.1) | 1.0 (1.0 to 1.1) |
| ST1 Day 57 | — | 2.1 (1.6 to 2.8) | 1.8 (1.4 to 2.3) | 1.0 (0.9 to 1.1) |
| ST1 Day 85 | — | 4.5 (3.3 to 6.1) | 4.5 (3.3 to 6.0) | 1.0 (1.0 to 1.1) |
| ST1 Day 180 | — | 1.7 (1.4 to 2.1) | 1.6 (1.3 to 1.9) | 1.0 (1.0 to 1.1) |
| ST1 Day 236 | — | 1.2 (1.0 to 1.5) | 1.3 (1.1 to 1.5) | 1.0 (1.0 to 1.1) |
| ST1 Day 365 | — | 1.2 (1.0 to 1.3) | 1.1 (1.0 to 1.2) | 1.0 (0.9 to 1.1) |
| ST2 Day 29 | — | 1.1 (0.9 to 1.3) | 1.1 (1.0 to 1.2) | 1.0 (1.0 to 1.1) |
| ST2 Day 57 | — | 4.4 (3.2 to 6.1) | 4.1 (3.0 to 5.5) | 1.0 (1.0 to 1.1) |
| ST2 Day 85 | — | 12.3 (9.5 to 15.8) | 13.3 (10.2 to 17.2) | 1.0 (1.0 to 1.1) |
| ST2 Day 180 | — | 2.9 (2.3 to 3.8) | 2.9 (2.2 to 3.7) | 1.0 (1.0 to 1.1) |
| ST2 Day 236 | — | 1.5 (1.2 to 1.9) | 1.6 (1.2 to 2.2) | 1.0 (1.0 to 1.0) |
| ST2 Day 365 | — | 1.2 (1.1 to 1.5) | 1.2 (1.1 to 1.4) | 1.0 (1.0 to 1.1) |
| ST3 Day 29 | — | 1.1 (1.0 to 1.4) | 1.0 (1.0 to 1.0) | 1.1 (0.9 to 1.2) |
| ST3 Day 57 | — | 6.1 (4.3 to 8.7) | 5.9 (4.3 to 8.2) | 1.1 (0.9 to 1.2) |
| ST3 Day 85 | — | 12.5 (9.6 to 16.4) | 12.8 (9.7 to 17.0) | 1.1 (0.9 to 1.2) |
| ST3 Day 180 | — | 3.3 (2.6 to 4.2) | 3.0 (2.3 to 3.8) | 1.1 (1.0 to 1.2) |
| ST3 Day 236 | — | 1.7 (1.3 to 2.2) | 1.8 (1.4 to 2.5) | 1.1 (0.9 to 1.3) |
| ST3 Day 365 | — | 1.3 (1.1 to 1.5) | 1.2 (1.1 to 1.4) | 1.1 (0.9 to 1.2) |
| ST4 Day 29 | — | 1.1 (0.9 to 1.3) | 1.1 (1.0 to 1.1) | 1.0 (1.0 to 1.0) |
| ST4 Day 57 | — | 2.7 (2.0 to 3.7) | 2.6 (2.0 to 3.3) | 1.0 (1.0 to 1.0) |
| ST4 Day 85 | — | 7.4 (5.7 to 9.7) | 7.9 (6.1 to 10.2) | 1.0 (1.0 to 1.0) |
| ST4 Day 180 | — | 2.2 (1.8 to 2.8) | 2.1 (1.7 to 2.5) | 1.0 (1.0 to 1.0) |
| ST4 Day 236 | — | 1.4 (1.2 to 1.7) | 1.4 (1.1 to 1.7) | 1.1 (0.9 to 1.2) |
| ST4 Day 365 | — | 1.2 (1.0 to 1.4) | 1.1 (1.0 to 1.3) | 1.1 (1.0 to 1.2) |
| ST5 Day 29 | — | 1.1 (0.9 to 1.2) | 1.0 (1.0 to 1.1) | 1.0 (1.0 to 1.0) |
| ST5 Day 57 | — | 2.9 (2.1 to 3.8) | 2.8 (2.1 to 3.6) | 1.0 (1.0 to 1.0) |
| ST5 Day 85 | — | 7.8 (5.9 to 10.3) | 8.1 (6.2 to 10.6) | 1.0 (1.0 to 1.0) |
| ST5 Day 180 | — | 2.2 (1.8 to 2.8) | 2.0 (1.6 to 2.6) | 1.0 (1.0 to 1.1) |
| ST5 Day 236 | — | 1.4 (1.2 to 1.8) | 1.5 (1.2 to 1.9) | 1.1 (0.9 to 1.2) |
| ST5 Day 365 | — | 1.1 (1.0 to 1.3) | 1.1 (1.0 to 1.2) | 1.0 (1.0 to 1.1) |
| ST6 Day 29 | — | 1.1 (0.9 to 1.2) | 1.1 (1.0 to 1.2) | 1.0 (1.0 to 1.0) |
| ST6 Day 57 | — | 2.6 (1.9 to 3.4) | 2.6 (2.0 to 3.4) | 1.0 (1.0 to 1.0) |
| ST6 Day 85 | — | 7.9 (6.1 to 10.4) | 8.7 (6.7 to 11.3) | 1.0 (1.0 to 1.0) |
| ST6 Day 180 | — | 2.3 (1.9 to 2.9) | 2.3 (1.8 to 2.9) | 1.1 (1.0 to 1.2) |
| ST6 Day 236 | — | 1.4 (1.1 to 1.7) | 1.5 (1.2 to 1.9) | 1.1 (0.9 to 1.3) |
| ST6 Day 365 | — | 1.2 (1.0 to 1.3) | 1.1 (1.0 to 1.3) | 1.1 (1.0 to 1.2) |
Frequency of SAEs (Serious Adverse Events) during the entire study; frequency is being assessed in terms of percentage of participants.
| percentage of participants | VLA15 Low Dose | VLA15 Medium Dose | VLA15 High Dose | Placebo |
|---|---|---|---|---|
| Percentage of Participants With SAEs (Serious Adverse Events) | 0.0 (0.0 to 11.7) | 1.9 (0.7 to 4.7) | 2.4 (1.0 to 5.6) | 2.4 (0.8 to 6.9) |
Frequency of related SAEs (Serious Adverse Events) during the entire study; frequency is being assessed in terms of percentage of participants.
| percentage of participants | VLA15 Low Dose | VLA15 Medium Dose | VLA15 High Dose | Placebo |
|---|---|---|---|---|
| Percentage of Participants With Related SAEs (Serious Adverse Events) | 0.0 (0.0 to 11.7) | 0.0 (0.0 to 1.8) | 0.0 (0.0 to 1.8) | 0.0 (0.0 to 3.0) |
Frequency of AESIs (Adverse Events of Special Interest) during the entire study; frequency is being assessed in terms of percentage of participants. AESIs are cases of Lyme Diseases, Lyme associated Events and the onset of potentially autoimmune or neuro-inflammatory disorders.
| percentage of participants | VLA15 Low Dose | VLA15 Medium Dose | VLA15 High Dose | Placebo |
|---|---|---|---|---|
| Percentage of Participants With AESIs (Adverse Events of Special Interest) | 0.0 (0.0 to 11.7) | 1.9 (0.7 to 4.7) | 0.5 (0.1 to 2.7) | 0.0 (0.0 to 3.0) |
Frequency of related AESIs (Adverse Events of Special Interest) during the entire study; frequency is being assessed in terms of percentage of participants. AESIs are cases of Lyme Diseases, Lyme associated Events and the onset of potentially autoimmune or neuro-inflammatory disorders.
| percentage of participants | VLA15 Low Dose | VLA15 Medium Dose | VLA15 High Dose | Placebo |
|---|---|---|---|---|
| Percentage of Participants With Related AESIs (Adverse Events of Special Interest) | 0.0 (0.0 to 11.7) | 0.5 (0.1 to 2.6) | 0.0 (0.0 to 1.8) | 0.0 (0.0 to 3.0) |
Frequency of unsolicited AEs (Adverse Events) during the entire study (incl. clinically relevant laboratory parameters); frequency is being assessed in terms of percentage of participants.
| percentage of participants | VLA15 Low Dose | VLA15 Medium Dose | VLA15 High Dose | Placebo |
|---|---|---|---|---|
| Percentage of Participants With Unsolicited AEs (Adverse Events) | 27.6 (14.7 to 45.7) | 51.9 (45.2 to 58.5) | 56.6 (49.7 to 63.2) | 51.6 (42.9 to 60.2) |
Frequency of related unsolicited AEs (Adverse Events) during the entire study (incl. clinically relevant laboratory parameters); frequency is being assessed in terms of percentage of participants.
| percentage of participants | VLA15 Low Dose | VLA15 Medium Dose | VLA15 High Dose | Placebo |
|---|---|---|---|---|
| Percentage of Participants With Related Unsolicited AEs (Adverse Events) | 6.9 (1.9 to 22.0) | 9.3 (6.1 to 14.0) | 14.6 (10.4 to 20.1) | 8.9 (5.0 to 15.2) |
Frequency of solicited local and solicited systemic AEs (Adverse Events) within 7 days after each and after any vaccination; frequency is being assessed in terms of percentage of participants.
| percentage of participants | VLA15 Low Dose | VLA15 Medium Dose | VLA15 High Dose | Placebo |
|---|---|---|---|---|
| Solicted Local AEs | 89.7 (73.6 to 96.4) | 93.0 (88.8 to 95.7) | 96.1 (92.5 to 98.0) | 29.8 (22.5 to 38.4) |
| Solicited Systemic AEs | 62.1 (44.0 to 77.3) | 67.8 (61.2 to 73.7) | 71.7 (65.2 to 77.4) | 42.7 (34.4 to 51.5) |
Frequency of SAEs (Serious Adverse Events), AESIs (Adverse Events of Special Interest), solicited and unsolicited AEs (Adverse Events) during the entire study stratified by age group - Group 18-49; frequency is being assessed in terms of percentage of participants.
| percentage of participants | VLA15 Low Dose | VLA15 Medium Dose | VLA15 High Dose | Placebo |
|---|---|---|---|---|
| SAEs | 0.0 (0.0 to 11.7) | 2.0 (0.7 to 5.8) | 2.1 (0.7 to 5.9) | 1.1 (0.2 to 6.0) |
| AESIs | 0.0 (0.0 to 11.7) | 0.7 (0.1 to 3.8) | 0.0 (0.0 to 2.6) | 0.0 (0.0 to 4.1) |
| solicited AEs | 89.7 (73.6 to 96.4) | 93.9 (88.8 to 96.7) | 96.6 (92.2 to 98.5) | 56.0 (45.8 to 65.8) |
| unsolicited AEs | 27.6 (14.7 to 45.7) | 49.0 (41.0 to 57.0) | 55.2 (47.0 to 63.0) | 50.5 (40.5 to 60.6) |
Frequency of SAEs (Serious Adverse Events), AESIs (Adverse Events of Special Interest), Solicited and Unsolicited AEs (Adverse Events) during the entire study stratified by age group - Group 50-65 years; frequency is being assessed in terms of percentage of participants.
| percentage of participants | VLA15 Low Dose | VLA15 Medium Dose | VLA15 High Dose | Placebo |
|---|---|---|---|---|
| SAEs | — | 1.5 (0.3 to 8.0) | 3.3 (0.9 to 11.4) | 6.1 (1.7 to 19.6) |
| AESIs | — | 4.5 (1.5 to 12.4) | 1.7 (0.3 to 8.9) | 0.0 (0.0 to 10.4) |
| solicited AEs | — | 92.5 (83.7 to 96.8) | 96.7 (88.6 to 99.1) | 51.5 (35.2 to 67.5) |
| unsolicited AEs | — | 58.2 (46.3 to 69.3) | 60.0 (47.4 to 71.4) | 54.5 (38.0 to 70.2) |
| Number of participants | VLA15 Low Dose | VLA15 Medium Dose | VLA15 High Dose | Placebo |
|---|---|---|---|---|
| Any AE of Special Interest | 0 | 4 | 1 | 0. |
| Lyme disease | 0 | 2 | 0 | 0 |
| Erythema migrans | 0 | 1 | 0 | 0 |
| Osteoarthritis | 0 | 1 | 0 | 0 |
| Polyarthritis | 0 | 0 | 1 | 0 |
Collected over up to Day 365. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| VLA15 Low Dose | 0/29 (0%) | 0/29 (0%) | 26/29 (89.7%) |
| VLA15 Medium Dose | 0/214 (0%) | 4/214 (1.9%) | 203/214 (94.9%) |
| VLA15 High Dose | 0/205 (0%) | 5/205 (2.4%) | 202/205 (98.5%) |
| Placebo | 0/124 (0%) | 3/124 (2.4%) | 85/124 (68.5%) |
| Event | VLA15 Low Dose | VLA15 Medium Dose | VLA15 High Dose | Placebo |
|---|---|---|---|---|
| DiverticulitisInfections and infestations | 0/29 | 0/214 | 0/205 | 1/124 |
| NeurosyphilisInfections and infestations | 0/29 | 0/214 | 0/205 | 1/124 |
| Acute myocardial infarctionCardiac disorders | 0/29 | 0/214 | 0/205 | 1/124 |
| Biliary colicHepatobiliary disorders | 0/29 | 0/214 | 0/205 | 1/124 |
| Herpes zosterInfections and infestations | 0/29 | 0/214 | 1/205 | 0/124 |
| Multiple injuriesInjury, poisoning and procedural complications | 0/29 | 0/214 | 1/205 | 0/124 |
| Upper limb fractureInjury, poisoning and procedural complications | 0/29 | 0/214 | 1/205 | 0/124 |
| PlasmacytomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/29 | 0/214 | 1/205 | 0/124 |
| Peripheral arterial occlusive diseaseVascular disorders | 0/29 | 0/214 | 1/205 | 0/124 |
| CellulitisInfections and infestations | 0/29 | 1/214 | 0/205 | 0/124 |
| Event | VLA15 Low Dose | VLA15 Medium Dose | VLA15 High Dose | Placebo |
|---|---|---|---|---|
| Injection site painGeneral disorders | 26/29 | 198/214 | 196/205 | 30/124 |
| MyalgiaMusculoskeletal and connective tissue disorders | 15/29 | 106/214 | 97/205 | 21/124 |
| HeadacheNervous system disorders | 10/29 | 73/214 | 84/205 | 33/124 |
| FatigueGeneral disorders | 8/29 | 66/214 | 81/205 | 29/124 |
| Injection site erythemaGeneral disorders | 8/29 | 68/214 | 72/205 | 12/124 |
| Injection site swellingGeneral disorders | 4/29 | 57/214 | 68/205 | 4/124 |
| Injection site indurationGeneral disorders | 3/29 | 64/214 | 65/205 | 2/124 |
| Influenza like illnessGeneral disorders | 3/29 | 32/214 | 42/205 | 20/124 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 2/29 | 42/214 | 37/205 | 12/124 |
| NauseaGastrointestinal disorders | 5/29 | 23/214 | 32/205 | 11/124 |
| Age, Continuous(years) | VLA15 Low Dose | VLA15 Medium Dose | VLA15 High Dose | Placebo | Total |
|---|---|---|---|---|---|
| Mean | 29.2 ± 6.13 | 41.7 ± 13.26 | 41.6 ± 12.56 | 40.7 ± 12.80 | 40.8 ± 12.90 |
| Sex: Female, Male(Participants) | VLA15 Low Dose | VLA15 Medium Dose | VLA15 High Dose | Placebo | Total |
|---|---|---|---|---|---|
| Female | 16 | 117 | 108 | 71 | 312 |
| Male | 13 | 97 | 97 | 53 | 260 |
| Race/Ethnicity, Customized(number of participants) | VLA15 Low Dose | VLA15 Medium Dose | VLA15 High Dose | Placebo | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 1 | 0 | 0 | 1 |
| Asian | 0 | 2 | 0 | 0 | 2 |
| Black or African American | 4 | 3 | 6 | 4 | 17 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| White | 25 | 208 | 196 | 120 | 549 |
| Other | 0 | 0 | 3 | 0 | 3 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Dec 2018 to primary completion in Dec 2019, 12 months.
Results were first posted in Jun 2021, 1 year 6 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: VLA15